The in vivo CRO market involves conducting various preclinical studies and evaluations using live animal and human models. In vivo evaluations are crucial for assessing toxicity, biopharmaceutical properties, and efficacy during the drug development process. Contract research organizations play a vital role in streamlining preclinical research by offering specialized services and infrastructure for conducting in vivo studies.

The global in vivo CRO market is estimated to be valued at USD 4.70 Bn in 2024 and is expected to reach USD 8.31 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031.

Key players operating in the in vivo CRO market include IQVIA Inc., Crown Bioscience, Taconic Biosciences, Inc., PsychoGenics Inc., Evotec, Janvier Labs, Biocytogen Boston Corp, GemPharmatech, Charles River Laboratories, Icon Plc, Labcorp Drug Development, Parexel International Corporation, SMO Clinical Research (I) Pvt Ltd., WuXi AppTec, ICON plc, and Syneos Health. These players provide customized preclinical research solutions and help accelerate drug development.

Key Takeaways

Key players: Key players operating in the in vivo CRO market are IQVIA Inc., Crown Bioscience, Taconic Biosciences, Inc., PsychoGenics Inc., Evotec, Janvier Labs, Biocytogen Boston Corp, GemPharmatech, Charles River Laboratories, Icon Plc, Labcorp Drug Development, Parexel International Corporation, SMO Clinical Research (I) Pvt Ltd., WuXi AppTec, ICON plc, and Syneos Health.

Key opportunities: The rising R&D investment in drug development and shift towards biomarker-driven drug discovery offers significant growth opportunities for players in the In Vivo CRO Market Size. Moreover, the growing acceptance of 3D bioprinting and human-on-a-chip models for preclinical drug efficacy and toxicity testing will further accelerate market revenues.

Technological advancements: Major technological advancements include the development of more human-relevant preclinical models incorporating disease microenvironments, organ-on-a-chip platforms, and 3D bioprinted tissue and organ mimics. These advanced disease models can provide translatable insights for clinical trials compared to traditional animal studies.

Market Drivers

A key driver for the in vivo CRO market is the rising complexity of drug molecules under development and stringent regulations surrounding preclinical safety evaluation. Biologics, cell and gene therapies require specialized bioanalytical characterization and safety pharmacology assessments using disease-relevant in vivo models. Thus, pharmaceutical companies rely on CROs to seamlessly navigate regulatory guidelines and accelerate preclinical research. This will continue to boost the demand for in vivo CRO outsourcing over the forecast period.

Challenges in the In Vivo CRO market

The In Vivo CRO Market Challenges and Opportunities is facing several challenges currently. Finding suitable animal models and ensuring translatability of preclinical data to humans remains a major issue. Ethical concerns around animal testing are also mounting. Strict regulations around laboratory animal welfare have increased compliance costs. There is a rising need for specialized preclinical services but lack of trained professionals. New cell and gene therapy areas require sophisticated large animal models which are difficult to source. Sustaining growth with pricing pressures from sponsors is another challenge.

Get more insights on In Vivo CRO Market